KR970706825A - A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER) - Google Patents
A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER)Info
- Publication number
- KR970706825A KR970706825A KR1019970702879A KR19970702879A KR970706825A KR 970706825 A KR970706825 A KR 970706825A KR 1019970702879 A KR1019970702879 A KR 1019970702879A KR 19970702879 A KR19970702879 A KR 19970702879A KR 970706825 A KR970706825 A KR 970706825A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- formula
- carbon atoms
- hydrogen atom
- helicobacter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
헬리코박터의 감염에 기인하는 소화기 질환의 치료제에 관한 것으로, 화학식(Ⅰ) 또는 (Ⅱ)로 나타내는 리파마이신 유도체 또는 그의 생리적으로 허용되는 염을 유효 성분으로서 함유하는 것을 특징으로 한다 :The present invention relates to a therapeutic agent for gastrointestinal diseases caused by infection with Helicobacter, and is characterized by containing, as an active ingredient, a rifamycin derivative represented by the formula (I) or (II) or a physiologically acceptable salt thereof:
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.
Claims (3)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP95-225317 | 1995-09-01 | ||
JP95-225318 | 1995-09-01 | ||
JP22531895 | 1995-09-01 | ||
JP22531795 | 1995-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970706825A true KR970706825A (en) | 1997-12-01 |
KR100407849B1 KR100407849B1 (en) | 2004-05-07 |
Family
ID=26526564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970702879A KR100407849B1 (en) | 1995-09-01 | 1996-08-29 | Therapeutic agent for diseases caused by infection of Helicobacter |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0787494B1 (en) |
KR (1) | KR100407849B1 (en) |
CA (1) | CA2204007A1 (en) |
DE (1) | DE69632677T2 (en) |
ES (1) | ES2218597T3 (en) |
TW (1) | TW385250B (en) |
WO (1) | WO1997009047A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981522A (en) * | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
KR100407851B1 (en) * | 1997-02-28 | 2004-04-29 | 가네가후치 가가쿠고교 가부시키가이샤 | Treatment of diseases caused by Helicobacter infection |
EP1057487A4 (en) * | 1998-02-24 | 2006-09-20 | Activbiotics Inc | Antimicrobial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
US6316433B1 (en) * | 1998-12-18 | 2001-11-13 | Kaneka Corporation | Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
WO2005020894A2 (en) * | 2003-08-22 | 2005-03-10 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
WO2005058231A2 (en) | 2003-12-10 | 2005-06-30 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
CA2550729A1 (en) | 2003-12-23 | 2005-07-14 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
DK2270133T3 (en) | 2008-04-22 | 2015-09-07 | Corporación Alimentaria Peñasanta Capsa | Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL130099C (en) * | 1963-10-11 | |||
DE2626296C2 (en) * | 1975-06-13 | 1986-11-27 | Farmitalia Carlo Erba S.p.A., Mailand/Milano | Rifamycin compound and process for its preparation |
IT1056272B (en) * | 1975-06-13 | 1982-01-30 | Archifar Ind Chim Trentino | PRODUCTS DERIVED FROM AROMATIC AMINES |
JPS59231092A (en) * | 1983-06-11 | 1984-12-25 | Kanebo Ltd | Phenothiazine-type rifamycin and its pharmaceutical use |
JPS63183587A (en) * | 1985-02-05 | 1988-07-28 | Kanegafuchi Chem Ind Co Ltd | Benzoxazino-rifamycin derivative |
CA1304363C (en) * | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
-
1996
- 1996-08-29 ES ES96928723T patent/ES2218597T3/en not_active Expired - Lifetime
- 1996-08-29 EP EP96928723A patent/EP0787494B1/en not_active Expired - Lifetime
- 1996-08-29 KR KR1019970702879A patent/KR100407849B1/en not_active IP Right Cessation
- 1996-08-29 DE DE69632677T patent/DE69632677T2/en not_active Expired - Lifetime
- 1996-08-29 CA CA002204007A patent/CA2204007A1/en not_active Abandoned
- 1996-08-29 WO PCT/JP1996/002464 patent/WO1997009047A1/en active IP Right Grant
- 1996-09-05 TW TW085110867A patent/TW385250B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2218597T3 (en) | 2004-11-16 |
TW385250B (en) | 2000-03-21 |
EP0787494A1 (en) | 1997-08-06 |
KR100407849B1 (en) | 2004-05-07 |
EP0787494A4 (en) | 2000-04-26 |
WO1997009047A1 (en) | 1997-03-13 |
EP0787494B1 (en) | 2004-06-09 |
DE69632677T2 (en) | 2005-06-16 |
CA2204007A1 (en) | 1997-03-13 |
DE69632677D1 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950031068A (en) | Combined Treatment of Osteoporosis | |
IL205420A (en) | Immunoregulatory compounds and derivatives, pharmaceutical compositions and use thereof in treating inflammatory conditions of the gastrointestinal tract | |
KR940007022A (en) | Piperidine derivatives, their use in the preparation and treatment thereof | |
FR2762843B1 (en) | NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
KR940701264A (en) | Use of Macrolide Compounds for Ophthalmic Diseases | |
KR970707108A (en) | (DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS) | |
EP0992509A3 (en) | Novel macrolide derivatives | |
KR970706825A (en) | A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER) | |
RU2003134629A (en) | CEPHEMA COMPOUNDS | |
KR950016760A (en) | Hemorrhoids Treatment | |
KR910004191A (en) | Renal disease treatment | |
KR910016660A (en) | Di- and tetra-fluoro analogs of squalene as squalene epoxidase inhibitor | |
ATE73449T1 (en) | 2-PIPERAZINYL-2-OXO-AETHYLENE-SUBSTITUTED FLAVONOID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
KR890014480A (en) | 2-pyridylacetic acid derivative, preparation method thereof and pharmaceutical composition containing same | |
DE69018730D1 (en) | Oxazolopyridine derivatives, processes for their preparation and pharmaceutical preparations containing them. | |
KR880000432A (en) | 4 (3H) -oxo-5,6,7,8-tetrahydropyrido-2,3-d pyrimidine derivative | |
KR890016059A (en) | Phosphonoalkylpurine Derivatives | |
KR880009015A (en) | Alimercetoacetylsidoneimine, a preparation method thereof and use thereof | |
KR940701251A (en) | Cholesterol-lowering Tocopherol Homolog | |
OA08972A (en) | New N- (vinblastinoyl-23) derivatives of 1-amino-methylphosphonic acid, their preparation processes and pharmaceutical compositions containing them | |
KR970064604A (en) | Benzopyran derivatives and their use as therapeutic agents for heart disease | |
AP9801235A0 (en) | Erythromycin derivatives. | |
EP0233745A3 (en) | Chemical compounds | |
KR940000443A (en) | Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxide | |
KR910015301A (en) | Treatment of Sleep Apnea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20111028 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20121114 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |